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ABSTRACT
OBJECTIVES
To determine how soon after delivery the risk of post-
pregnancy hypertension increases in women with 
hypertensive disorders of pregnancy and how the risk 
evolves over time.
DESIGN
Nationwide register based cohort study.
SETTING
Denmark.
POPULATIONS
482 972 primiparous women with a first live birth 
or stillbirth between 1995 and 2012 (cumulative 
incidence analyses), and 1 025 118 women with at 
least one live birth or stillbirth between 1978 and 
2012 (Cox regression analyses).
MAIN OUTCOME MEASURES
10 year cumulative incidences of post-pregnancy 
hypertension requiring treatment with prescription 
drugs, and hazard ratios estimated using Cox 
regression.
RESULTS
Of women with a hypertensive disorder of pregnancy 
in a first pregnancy in their 20s, 14% developed 
hypertension in the first decade post partum, 
compared with 4% of women with normotensive 
first pregnancies in their 20s. The corresponding 
percentages for women with a first pregnancy in their 
40s were 32% and 11%, respectively. In the year 
after delivery, women with a hypertensive disorder 
of pregnancy had 12-fold to 25-fold higher rates of 
hypertension than did women with a normotensive 
pregnancy. Rates in women with a hypertensive 
disorder of pregnancy were threefold to 10-fold higher 
1-10 years post partum and remained twice as high 
even 20 or more years later.
CONCLUSIONS
The risk of hypertension associated with hypertensive 
disorders of pregnancy is high immediately after an 
affected pregnancy and persists for more than 20 
years. Up to one third of women with a hypertensive 
disorder of pregnancy may develop hypertension 
within a decade of an affected pregnancy, indicating 
that cardiovascular disease prevention in these 
women should include blood pressure monitoring 
initiated soon after pregnancy.
Introduction
Hypertensive disorders of pregnancy (pre-eclampsia; 
eclampsia; haemolysis, elevated liver enzymes, and 
low platelets (HELLP) syndrome; and gestational 
hypertension) affect up to 10% of pregnancies.1 2 
Women with a hypertensive disorder of pregnancy 
have increased risks of post-pregnancy hypertension, 
ischaemic heart disease, and stroke,3-5 which has 
prompted changes to guidelines by the American 
Heart Association and the European Society of 
Cardiology to include hypertensive disorders of 
pregnancy as risk factors for cardiovascular disease 
in women.6 7 However, clinical awareness of the link 
between hypertensive disorders of pregnancy and 
cardiovascular disease is incomplete,8-10 which may 
result in delayed diagnosis and jeopardise the health 
of these women. Furthermore, it is unclear how soon 
after an affected pregnancy screening for hypertension 
and other markers of cardiovascular disease should be 
initiated.2 6 11 Recent work suggests that the immediate 
postpartum years are important, with one study 
reporting a fivefold increase in hypertension rates in 
the first five years after a pre-eclamptic pregnancy,12 
and another finding that 25-45% of women with 
a hypertensive disorder of pregnancy developed 
hypertension within five years of delivery.13 However, 
precisely when the increased risk of hypertension 
appears after a pregnancy affected by a hypertensive 
disorder of pregnancy and how the risk changes with 
time since pregnancy remain unclear. Understanding 
patterns of hypertension risk after a hypertensive 
disorder of pregnancy would enable clinicians to plan 
appropriate post-pregnancy follow-up and diagnose 
hypertension as early as possible.
In a cohort of more than one million women delivering 
in Denmark in 1978-2012, we examined the timing and 
1Department of Epidemiology 
Research, Statens Serum 
Institut, Artillerivej 5, DK-2300 
Copenhagen S, Denmark
2Department of Obstetrics, 
Copenhagen University Hospital 
(Rigshospitalet), Copenhagen, 
Denmark
3The Heart Centre, Copenhagen 
University Hospital 
(Rigshospitalet), Copenhagen, 
Denmark
4Fetal Medicine Unit, 
St George’s Hospital, University 
of London, London, UK
Correspondence to: H A Boyd 
hoy@ssi.dk
Additional material is published 
online only. To view please visit 
the journal online.
Cite this as: BMJ 2017;358:j3078 
http://dx.doi.org/10.1136/bmj.j3078
Accepted: 17 June 2017
WHAT IS ALREADY KNOWN ON THIS TOPIC
 Women with a history of hypertensive disorders of pregnancy have a twofold to 
fourfold increased post-pregnancy risk of developing essential hypertension, an 
important risk factor for cardiovascular disease
It is unclear how soon after delivery the risk of hypertension increases in women 
with hypertensive disorders of pregnancy
It is also unclear how the risk changes with time since pregnancy, and therefore, 
there is no evidence on which to base recommendations for clinical follow-up of 
these women
WHAT THIS STUDY ADDS
Women had substantially increased risks of post-pregnancy hypertension in 
the decade after a hypertensive disorder of pregnancy (14-32% after a first 
pregnancy, depending on age at delivery)
Cardiovascular disease prevention in women with hypertensive disorders 
of pregnancy should include blood pressure monitoring initiated soon after 
pregnancy
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trajectory of post-pregnancy hypertension risk on a fine 
temporal scale, in women with and without a history 
of hypertensive disorders of pregnancy. Specifically, 
we estimated cumulative incidences of post-pregnancy 
hypertension over the first 10 years post partum and 
compared rates of post-pregnancy hypertension in 
women with and without a hypertensive disorder of 
pregnancy, by time since most recent pregnancy.
Methods
Data sources
The Danish civil registration system continuously 
updates personal and vital status information through 
the unique personal identification number assigned 
to all Danish residents.14 Contacts with the healthcare 
system and filled prescriptions are registered using 
the personal identification number, enabling register 
based studies with little loss to follow-up. The 
national patient register contains information on 
hospital discharge diagnoses assigned since 1977 
and outpatient diagnoses assigned since 1995.15 The 
medical birth register contains information on live 
births and stillbirths since 1973, with gestational age at 
delivery from 1978.16 The national prescription register 
contains data on prescriptions filled since 1994.17
Study cohorts
In this study we used two cohorts: one for the 
estimation of cumulative incidence of post-pregnancy 
hypertension and the other cohort for the estimation of 
hazard ratios for post-pregnancy hypertension.
Cumulative incidences of post-pregnancy hypertension—
using the medical birth register, we identified all women 
with a first pregnancy lasting 20 or more weeks and 
ending in live birth or stillbirth between 1995 and 2012. 
We excluded women with any cardiac or circulatory 
system disorder (international classification of diseases, 
eighth revision (ICD-8), codes 390-458, or 10th revision 
(ICD-10) codes I00.0-I99.9) registered in the national 
patient register before their first delivery, and women 
with known or potential pregestational hypertension.
Hazard ratios for post-pregnancy hypertension—
using the medical birth register, we identified all 
women who had at least one pregnancy that lasted 
20 or more weeks and ended in live birth or stillbirth 
between 1978 and 2012, and who were living in 
Denmark at some point during the follow-up period, 
1995-2012. We excluded women with any cardiac or 
circulatory system disorder registered in the national 
patient register before their first delivery or before 
1995, whichever came later, and women with known 
or potential pregestational hypertension.
Hypertensive disorders of pregnancy (exposure)
We considered women to have a hypertensive 
disorder of pregnancy in a given pregnancy if they 
had a diagnosis of gestational hypertension, pre-
eclampsia, eclampsia, or HELLP syndrome registered 
in the national patient register any time between one 
month before delivery and seven days post partum. 
To be considered exposed to a hypertensive disorder 
of pregnancy in our study, women with diagnoses 
registered outside this time window also had to have at 
least one diagnosis registered within the window. (We 
adopted this restriction to try to ensure that diagnoses 
of hypertensive disorders of pregnancy reflected true 
cases; we judged that assigning a hypertensive disorder 
of pregnancy designation would be questionable if 
a woman’s only hypertensive disorder of pregnancy 
diagnoses were registered outside this time window, 
particularly if a diagnosis was assigned many weeks 
before delivery and never alluded to again.) Since by 
definition a hypertensive disorder of pregnancy involves 
incident hypertension in a pregnant woman with onset 
after 20 weeks’ gestation, we considered only diagnoses 
registered after this point. As registered in the national 
patient register, gestational hypertension is defined 
as hypertension without accompanying proteinuria 
(ICD-8 code 637.00, ICD-10 code O13.9 or O16.9), 
whereas in moderate pre-eclampsia, mild or moderate 
hypertension is accompanied by proteinuria (ICD-8 
codes 637.03, 637.09, or 637.99, ICD-10 code O14.0 
or O14.9). Severe pre-eclampsia fulfills the criteria for 
moderate pre-eclampsia, with the addition of one or 
more of severe hypertension, severe proteinuria, signs 
of organ failure (including the HELLP syndrome), or 
generalised seizures (ICD-8 codes 637.04, 637.19, 
762.19, 762.29, or 762.39, ICD-10 codes O14.1, 
O14.2, or O15.0-15.9). If a woman was registered with 
more than one hypertensive disorder of pregnancy in a 
single pregnancy, we classified her as having the most 
severe disorder registered. In an additional analysis, 
we used an alternative categorisation for hypertensive 
disorders of pregnancy whereby we classified the 
condition as early onset for deliveries at less than 34 
weeks’ gestation, intermediate onset for deliveries at 
34-36 weeks, and term for deliveries at 37 or more 
weeks, regardless of the severity of the registered 
hypertensive disorder of pregnancy.
Hypertension (outcome)
We considered a woman to have new onset post-
pregnancy hypertension from the time she filled 
a second prescription for antihypertensive drugs 
(Anatomic Therapeutic Chemical codes C02-03 or 
C07-09 registered in the national prescription register) 
within a six month period. When defining hypertension 
we ignored antihypertensive drug use that was 
potentially related to treatment for hypertensive 
disorders of pregnancy (use from 20 weeks before 
delivery to three months post partum).
Exclusion of women with known or potential 
pregestational hypertension
In the cumulative incidence analyses we considered 
women with antihypertensive drug use before their 
first pregnancy or up to 20 weeks’ gestation in that first 
pregnancy to have pregestational hypertension and 
excluded them from the cohort.
In the relative risk analyses we excluded women 
with pregnancies before 1994 (ie, predating the 
national prescription register) who filled prescriptions 
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for antihypertensive drugs in 1994, as we did not 
know whether hypertension was pregestational or 
post-gestational in women using drugs at the start 
of follow-up. Similarly, we excluded women with a 
first pregnancy in 1994 if they filled prescriptions for 
antihypertensive drugs before 20 weeks’ gestation or 
3-12 months after delivery (ie, beyond the period when 
such treatment could be associated with pregnancy 
related hypertension) since we did not know if 
this use began before or after pregnancy. We also 
excluded women with a first pregnancy after 1995 and 
antihypertensive drug use before 20 weeks’ gestation 
in that pregnancy.
Covariates
Age, maternal birth year, parity, diabetes, smoking, 
and body mass index were considered a priori to be 
potential confounders of an association between 
hypertensive disorders of pregnancy and later 
hypertension. Information on age and maternal birth 
year (civil registration system), parity (medical birth 
register), and diabetes (types 1 and 2, national patient 
register, ICD-8 codes 249.00-249.09 or 250.00-
250.09, ICD-10 codes E10.0-E11.9) was available for 
the entire study period. Information on first trimester 
smoking status and prepregnancy body mass index 
(medical birth register) was available from 1991 and 
2004 onwards, respectively.
Statistical analyses
To calculate 10 year cumulative incidences of 
hypertension, we followed women from three 
months after their first delivery until the first of: 
hypertension, 10 years after the first delivery, death, 
emigration, “missing” in the civil registration system, 
or 31 December 2012. For women with at least two 
pregnancies, we also conducted similar analyses for 
the decade after the second delivery.
For the estimation of relative risks of post-pregnancy 
hypertension we followed women from 1 January 
1995 or three months after their first delivery in the 
study period, whichever came later, until the first of: 
hypertension, death, emigration, “missing” in the civil 
registration system, or 31 December 2012. Using Cox 
regression with maternal age as the underlying time, we 
estimated hazard ratios for post-pregnancy hypertension 
by history of hypertensive disorders of pregnancy. 
Firstly, we estimated hazard ratios by number of years 
since a woman’s most recent pregnancy, to examine 
the immediate effect of a hypertensive disorder of 
pregnancy on subsequent risk of hypertension. In these 
analyses, hypertensive disorder of pregnancy status 
was a time dependent variable reflecting a woman’s 
experience in the most recent pregnancy and was 
updated for each subsequent pregnancy. Secondly, we 
estimated hazard ratios by most severe hypertensive 
disorder of pregnancy to date, stratified by attained 
age. History of hypertensive disorders of pregnancy 
was a “cumulative” time dependent variable, reflecting 
the most severe hypertensive disorder of pregnancy (if 
any) the woman had experienced to date. A woman’s 
status could switch from, for example, no hypertensive 
disorder of pregnancy to pre-eclampsia if the pre-
eclamptic pregnancy came later, but she could not 
revert to having no history of a hypertensive disorder 
of pregnancy if an unaffected pregnancy followed 
an affected one. Finally, in women with at least two 
pregnancies who were hypertension-free between 
pregnancies, we estimated hazard ratios comparing 
rates of hypertension in women with a hypertensive 
disorder of pregnancy in the first pregnancy, in the 
second pregnancy, or in both pregnancies, with rates in 
women with two normotensive pregnancies, by number 
of years since the second pregnancy. For women with 
more than two pregnancies, follow-up in these analyses 
ended at their third pregnancy.
In all Cox regression analyses, we stratified the 
baseline hazards by parity (1, 2, ≥3 live births and/
or stillbirths) and maternal birth year (five year 
intervals) to ensure that we compared rates in women 
of the same age and parity; including maternal birth 
year helped to account for possible time trends in 
hypertensive disorders of pregnancy and hypertension 
treatment. Analyses estimating hazard ratios by most 
severe hypertensive disorder of pregnancy to date were 
also adjusted for time since most recent pregnancy 
(<1 year, 1 year intervals from 1-9 years, 10-14 years, 
15-19 years, and ≥20 years). In sensitivity analyses in 
the full cohort, we additionally adjusted for diabetes 
as a time dependent variable (such that we considered 
women without diabetes at baseline who developed 
diabetes during follow-up to be without diabetes until 
their diagnosis, after which they contributed person 
time to the diabetes group). In subcohorts of women 
with available information, we further adjusted for 
smoking and prepregnancy body mass index. Smoking 
status (smoker or non-smoker) and prepregnancy body 
mass index (<18.5, 18.5-24, 25-29, 30-34, or ≥35) 
were considered as time independent variables based 
on information from the woman’s first pregnancy in 
or after 1991 and 2004, respectively. We evaluated 
violation of the proportional hazards assumption by 
plotting Martingale residuals against attained age.18
All analyses were performed using SAS statistical 
software, version 9.4 (SAS Institute, Cary, NC).
Patient involvement
No patients were involved in setting the research 
question or the outcome measures, nor were 
they involved in the design or implementation 
of the study. No patients were asked to advise on 
interpretation or writing up of results. There are no 
plans to disseminate the results of the research to 
study participants.
Results
10 year cumulative incidences of post-pregnancy 
hypertension
We identified 482 972 women with no cardiac or 
circulatory system disorders or hypertension registered 
before their first delivery and whose first delivery 
occurred in or after 1995. Of these women, 23 235 (4.8%) 
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had a hypertensive disorder of pregnancy in their first 
pregnancy, and 16 611 developed hypertension during 
follow-up. Women with a normotensive first pregnancy 
in their 20s, 30s, or 40s had cumulative incidences of 
hypertension of 4.0%, 5.7%, and 11.3%, respectively, in 
the decade after delivery (fig 1, supplementary table 1). 
The corresponding incidences for women whose first 
pregnancy was complicated by a hypertensive disorder of 
pregnancy were 13.7%, 20.3%, and 32.4%, respectively. 
A similar pattern was observed in the decade after a 
second pregnancy in women with two pregnancies, 
where either pregnancy could have been complicated by 
hypertensive disorders of pregnancy (see supplementary 
table 1).
Relative risks of post-pregnancy hypertension
After excluding women with cardiovascular disease 
(n=47 142) or pregestational hypertension (n=20 249), 
1 025 118 women had at least one eligible pregnancy 
between 1978 and 2012. Table 1 presents baseline 
characteristics of the women in this cohort by history of 
a hypertensive disorder of pregnancy in the pregnancy 
immediately preceding study entry. In this cohort, 
59 319 (5.8%) women had one or more pregnancies 
complicated by hypertensive disorders of pregnancy 
between 1978 and 2012; 183 423 developed 
hypertension during follow-up (1995-2012).
Hypertensive disorder of pregnancy in most recent 
pregnancy—in the year after a woman’s latest delivery, 
rates of post-pregnancy hypertension were 12-fold to 
25-fold higher in women with a hypertensive disorder 
of pregnancy than in women with a normotensive 
pregnancy (fig 2, supplementary table 2). One to 
five years post partum, rates were fourfold to 10-
fold higher in women with a hypertensive disorder 
of pregnancy in the latest pregnancy. Hazard ratios 
were lower thereafter, but even more than 20 years 
post partum, women with a hypertensive disorder of 
pregnancy in their most recent pregnancy had twice 
the rate of hypertension as women whose most recent 
pregnancy was normotensive. With the exception of 
the first year post partum, hazard ratios for gestational 
hypertension were statistically significantly higher 
than hazard ratios for pre-eclampsia, regardless of 
the time that had elapsed since pregnancy (fig  2, 
supplementary table  2). Observed association 
magnitudes did not differ statistically significantly 
by severity of pre-eclampsia. Additional adjustment 
for diabetes, smoking, and body mass index did not 
meaningfully change the results (see supplementary 
tables 3-5). In the first years after delivery, there was 
a tendency towards higher rates of hypertension in 
women with early onset hypertensive disorders of 
pregnancy, compared with women with intermediate 
onset or term hypertensive disorders of pregnancy, 
but overall, hazard ratios did not vary statistically 
significantly by timing of onset of the hypertensive 
disorder of pregnancy (see supplementary figure 1 and 
supplementary table 6).
History of hypertensive disorders of pregnancy—
rates of post-pregnancy hypertension were twofold to 
sixfold higher in women with a history of hypertensive 
disorders of pregnancy than in women the same age 
with only normotensive pregnancies, with the strongest 
associations in younger women (fig 3, supplementary 
table 7). For all but women aged less than 30 years, a 
history of gestational hypertension was more strongly 
associated with post-pregnancy hypertension than a 
history of pre-eclampsia, regardless of the severity of 
the pre-eclampsia.
Sequence of hypertensive disorders of pregnancy—
for women with at least two pregnancies, having a 
hypertensive disorder of pregnancy in the first pregnancy 
but not in the second was associated with a doubling 
of the rate of post-pregnancy hypertension, compared 
with having two normotensive pregnancies, regardless 
of the time elapsed since the second pregnancy (fig 4, 
supplementary table 8). The associations were even 
stronger in women with a normotensive first pregnancy 
and a hypertensive disorder of pregnancy in the second 
pregnancy, and greatest (hazard ratio range 2.6-7.8) in 
women with hypertensive disorders of pregnancy in 
both pregnancies.
Sensitivity analyses
Table 2 shows the distribution of antihypertensive drug 
use in the first year post partum among women with a first 
delivery in or after 1995. Some hypertension identified 
during this year might reflect undetected pregestational 
hypertension. Consequently, we examined the effect of 
excluding women who developed hypertension 3-12 
months post partum on our cumulative incidences 
and hazard ratios.  Follow-up began one year post 
partum, and in the analyses we included only women 
with no hypertension 3-12 months after delivery. 
Beginning follow-up one year post partum in women 
free of hypertension at that time slightly reduced the 
cumulative incidences for women with hypertensive 
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Fig 1 | Ten year cumulative incidences of hypertension by 
years since first pregnancy in women with and without 
a hypertensive disorder of pregnancy, by age at first 
delivery, Denmark, 1995-2012. Follow-up began in 1995 
or three months post partum, whichever came later
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disorders of pregnancy (see supplementary table 1). 
In the analyses of cumulative history of hypertensive 
disorders of pregnancy, hazard ratio magnitudes 
in women aged less than 35 years decreased (see 
supplementary table 9), whereas hazard ratios for older 
women changed little, if at all. Excluding women with 
early post-pregnancy hypertension from the analyses of 
hypertensive disorder of pregnancy sequence reduced 
the magnitudes of hazard ratios estimated for elapsed 
times of five years or less since the second pregnancy 
(see supplementary table 10).
Discussion
In a large nationwide cohort, 14-32% of women with 
a hypertensive disorder of pregnancy in their first 
pregnancy developed hypertension in the decade 
after delivery, compared with 4-11% of women 
with normotensive first pregnancies. Rates of post-
pregnancy hypertension in women with a hypertensive 
disorder of pregnancy in the most recent pregnancy 
were 12-fold to 25-fold higher in the first year post 
partum and up to 10-fold higher in the decade after 
delivery, than in women without a hypertensive 
disorder of pregnancy. Hypertension rates among 
women with a previous hypertensive disorder of 
pregnancy remained doubled more than 20 years later.
Our large cohort allowed us to examine the timing 
and trajectory of post-pregnancy hypertension risk 
associated with hypertensive disorders of pregnancy 
in short, discrete time intervals. Including all parous 
women in Denmark in the cohort minimised the 
possibility of selection bias, and using prospectively 
collected register data eliminated the possibility of 
recall bias. Validation of diagnoses for hypertensive 
disorders of pregnancy in the national patient register 
has shown that although their sensitivity is variable 
(such that some misclassification of pregnancies 
complicated by hypertensive disorders of pregnancy 
as normotensive almost certainly occurred), their 
specificity is excellent (>99%),19 and the potential 
impact of misclassification of hypertensive disorders 
of pregnancy diagnoses on the observed associations 
is therefore likely negligible. Although guidelines for 
the diagnosis of hypertensive disorders of pregnancy 
have changed in the past 35 years, most notably 
in the past decade, the blood pressure thresholds 
used to define gestational hypertension and pre-
Table 1 | Baseline characteristics of the study cohort used to estimate relative risks of post-pregnancy hypertension, at study entry, Denmark,  
1995-2012*. Values are numbers (percentages) unless stated otherwise
Characteristics Normotensive
Hypertensive disorder of pregnancy in most recent pregnancy†
Gestational hypertension Moderate pre-eclampsia Severe pre-eclampsia
Age (years):
 <20 14 138 (1.4) 56 (0.6) 314 (1.3) 134 (1.8)
 20-24 108 333 (11.0) 810 (9.3) 3006 (12.5) 1051 (14.0)
 25-29 279 569 (28.4) 2554 (29.4) 7590 (31.6) 2567 (34.2)
 30-34 258 279 (26.2) 2277 (26.2) 6089 (25.3) 2131 (28.4)
 35-39 166 099 (16.9) 1485 (17.1) 3555 (14.8) 1016 (13.5)
 40-44 102 678 (10.4) 888 (10.2) 2155 (9.0) 427 (5.7)
 45-49 44 445 (4.5) 467 (5.4) 1003 (4.2) 141 (1.9)
 ≥50 11 324 (1.2) 156 (1.8) 345 (1.4) 36 (0.5)
 Total 984 865 8693 24 057 7503
Parity:
 1 698 753 (70.9) 7087 (81.5) 19 955 (82.9) 6700 (89.3)
 2 220 210 (22.4) 1248 (14.4) 3281 (13.6) 634 (8.4)
 ≥3 65 902 (6.7) 358 (4.1) 821 (3.4) 169 (2.3)
 Total 984 865 8693 24 057 7503
Diabetes (type 1 or 2):
 Yes 4667 (0.5) 111 (1.3) 385 (1.6) 129 (1.7)
 No 980 198 (99.5) 8582 (98.7) 23 672 (98.4) 7374 (98.3)
 Total 984 865 8693 24 057 7503
First trimester smoking‡:
 Yes 162 644 (23.8) 1029 (15.5) 3314 (18.2) 847 (13.3)
 No 520 173 (76.2) 5592 (84.5) 14 879 (81.8) 5544 (86.8)
 Total 682 817 6621 18 193 6391
Prepregnancy body mass index§:
 <18.5 14 134 (4.5) 69 (1.8) 153 (2.1) 105 (3.5)
 18.5-24 203 234 (64.8) 1757 (46.4) 3608 (48.4) 1716 (57.0)
 25-29 63 288 (20.2) 1005 (26.5) 1983 (26.6) 687 (22.8)
 30-34 22 345 (7.1) 551 (14.6) 1030 (13.8) 310 (10.3)
 ≥35 10 649 (3.4) 405 (10.7) 686 (9.2) 194 (6.4)
 Total 313 650 3787 7460 3012
*Based on full cohort of women with one or more pregnancies between 1978 and 2012, unless indicated otherwise (see ‡ and §).
†History of hypertensive disorder of pregnancy in most recent pregnancy before start of follow-up. Not all women with a pregnancy complicated by a hypertensive disorder of pregnancy 
had the disorder in the pregnancy immediately preceding the start of follow-up; history of a hypertensive disorder of pregnancy in the most recent pregnancy was a time dependent variable 
that was reset with every pregnancy during follow-up. Therefore, although 40 253 women had a history of a hypertensive disorder of pregnancy in the most recent pregnancy at the start of 
follow-up (as shown in this table), 59 319 had a pregnancy affected by a hypertensive disorder of pregnancy between 1978 and 2012 (as noted in the Results).
‡First trimester smoking status in woman’s first pregnancy resulting in live birth or stillbirth in 1991-2012.
§Prepregnancy body mass index in woman’s first pregnancy resulting in live birth or stillbirth in 2004-12.
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eclampsia, and the assumption that pre-eclampsia 
typically includes proteinuria, have been fairly 
consistent. Furthermore, major changes in definition 
put forward by the American College of Obstetrics and 
Gynecology,2 the Royal College of Obstetricians and 
Gynaecologists,11 and the International Society for the 
Study of Hypertension in Pregnancy,20 which allow 
for conditions other than proteinuria (eg, fetal growth 
restriction) to define pre-eclampsia, were published 
late in the study period or after the study period ended. 
Registration of filled prescriptions in the national 
prescription register occurs automatically through the 
personal identification number, which should ensure 
that registration of all dispensed drugs in Denmark 
is correct and virtually complete.17 However, women 
using antihypertensive drugs for other indications 
will have been misclassified as having hypertension. 
Hypertension rates based on drug use also 
underestimate the true rates in the study population, 
since not all hypertension is detected, and not all 
women with a diagnosis are treated.21 However, since 
clinical awareness of the link between hypertensive 
disorders of pregnancy and later cardiovascular disease 
remains incomplete,9 10 22 the probability of having 
a diagnosis of hypertension was unlikely to differ for 
women with and without a history of hypertensive 
disorders of pregnancy. Hypertension diagnosed 
within one year post partum was undoubtedly also a 
mixture of undetected prepregnancy hypertension and 
new onset hypertension. From a clinical perspective, 
however, whether hypertension detected post partum 
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Fig 2 | Hazard ratios for hypertension by severity of 
hypertensive disorder of pregnancy (if any) in the most 
recent pregnancy and time since most recent pregnancy, 
among women with at least one live birth or stillbirth in 
Denmark, 1978-2012. Hazard ratios compare rates of 
hypertension among women with severe pre-eclampsia 
(orange), moderate pre-eclampsia (green), and 
gestational hypertension (black) in the latest pregnancy 
with rates of hypertension in women whose most recent 
pregnancy was normotensive. Follow-up began in 1995 
or three months post partum, whichever came later. 
Hazard ratios are adjusted for maternal age, maternal 
birth year, and parity (see also supplementary figure 1 
for corresponding figure with hypertensive disorders of 
pregnancy classified by timing of delivery)
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Fig 3 | Hazard ratios for hypertension by history of 
most severe hypertensive disorder of pregnancy 
and attained maternal age, among women with at 
least one live birth or stillbirth in Denmark, 1978-
2012. Hazard ratios compare rates of hypertension 
among women with severe pre-eclampsia (orange), 
moderate pre-eclampsia (green), and gestational 
hypertension (black) as their most severe hypertensive 
disorder of pregnancy (cumulative history over all 
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came later. Hazard ratios are adjusted for maternal age, 
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disorder of pregnancy sequence in two first pregnancies 
by number of years since the second pregnancy, among 
women with at least two live births or stillbirths in 
Denmark, 1978-2012. Hazard ratios compare rates 
of hypertension among women with a hypertensive 
disorder of pregnancy in first pregnancy but not in 
the second (green), a normotensive first pregnancy 
followed by a hypertensive disorder of pregnancy in 
second pregnancy (red), and hypertensive disorders 
of pregnancy in two successive pregnancies (purple), 
with rates in women with two successive normotensive 
pregnancies. Follow-up began in 1995 or 3 months after 
the second delivery, whichever came later. Hazard ratios 
are adjusted for maternal age, maternal birth year, and 
parity
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predated the pregnancy or is a sequela of hypertensive 
disorders of pregnancy, is of minor importance; either 
way, women with a previous hypertensive disorder of 
pregnancy have much higher rates of hypertension 
than their peers, and clinical contact with these 
women therefore represents an important opportunity 
for detection. Adjustment for diabetes and smoking 
did not change the observed associations, suggesting 
that these variables could not explain our findings. 
Although adjustment for body mass index also did 
not substantially change our results, these analyses 
were underpowered and we cannot exclude the 
possibility that body mass index might play a role 
in the association between hypertensive disorders 
of pregnancy and post-pregnancy hypertension. We 
also cannot discount the possibility that unmeasured 
risk factors for hypertension (eg, alcohol and salt 
intake, stress) might have confounded the observed 
associations, but this is unlikely, since to do so 
these factors would also have to be associated with 
hypertensive disorders of pregnancy.
Most studies assessing hypertension risk after a 
hypertensive disorder of pregnancy have reported 
risks averaged over follow-up periods ranging from a 
few years to decades (eg,3-5 13). Apart from one study 
examining hazard ratios for hypertension in five year 
intervals after delivery,12 studies have not focused 
on hypertension risk specifically by time since a 
pregnancy complicated by a hypertensive disorder 
of pregnancy —that is, on the timing of hypertension 
onset and how the risk of hypertension changes 
over time. Our work indicates that the immediate 
postpartum years are important: the increased risks of 
hypertension associated with hypertensive disorders 
of pregnancy already exist shortly after an affected 
pregnancy. Furthermore, for women aged more than 
30 years, gestational hypertension was more strongly 
associated with post-pregnancy hypertension than 
was pre-eclampsia, which is consistent with findings 
from some,23 24 but not all,4 13 25 previous studies and 
is thought to reflect aetiological differences between 
gestational hypertension and pre-eclampsia.2627 
Hypertension during and after pre-eclampsia might 
be a marker of wider multiorgan system disruption, 
whereas the mechanisms underlying gestational 
hypertension may be more narrowly focused. An 
excess of undetected prepregnancy hypertension 
in women with gestational hypertension could also 
explain higher rates of hypertension immediately after 
an affected pregnancy, but differential detection of 
prepregnancy hypertension depending on later type of 
hypertensive disorder of pregnancy seems implausible. 
Furthermore, such an excess would not explain why 
risks remained larger for gestational hypertension than 
for pre-eclampsia decades after delivery.
Women with hypertensive disorders of pregnancy 
had much higher 10 year risks of post-pregnancy 
hypertension than did women of the same age with 
normotensive pregnancies. The substantial absolute 
risks of hypertension in the decade after a hypertensive 
disorder of pregnancy indicate that the processes 
linking hypertensive disorders of pregnancy and 
hypertension are already operational during or shortly 
after pregnancy. Whether the risk of hypertension 
(and later cardiovascular disease) in women with 
hypertensive disorders of pregnancy is due to common 
predisposing factors or to a downstream effect of 
pathophysiological processes specific to hypertensive 
disorders of pregnancy, is currently the focus of 
debate.28-30 Either hypothesis could explain the finding 
that women with hypertensive disorders of pregnancy 
in two pregnancies had higher risks of hypertension 
than women with one affected pregnancy. However, 
the finding that, among women with a hypertensive 
disorder of pregnancy in only one of two pregnancies, 
a hypertensive disorder of pregnancy in the second 
pregnancy was more strongly associated with later 
hypertension than a hypertensive disorder of pregnancy 
in the first pregnancy, argues against the importance 
of processes initiated by hypertensive disorders of 
pregnancy. If post-partum hypertension was the direct 
consequence of the hypertensive disorder of pregnancy 
itself, one would expect the effect of a single affected 
pregnancy to be the same regardless of sequence, after 
taking into account time since most recent pregnancy.
The study results suggest that the as yet poorly 
understood processes leading to hypertension related 
to hypertensive disorders of pregnancy begin while 
the affected women are still relatively young. At 
the very least, initiation of regular blood pressure 
assessments soon after a pregnancy complicated 
by a hypertensive disorder of pregnancy is essential 
for prompt identification of hypertension in these 
women. Because the number of women potentially at 
risk of hypertension related to hypertensive disorders 
of pregnancy is large, and routine follow-up could 
conceivably last years or even decades, an algorithm 
to identify those at greatest risk (the subgroup most 
likely to benefit from screening) is urgently needed; 
identification of biomarkers that predict which women 
Table 2 | Antihypertensive drug use in the year after first delivery in women without previous antihypertensive drug use, by history of hypertensive 
disorders of pregnancy in Denmark, 1995-2012*
Hypertensive disorder of  
pregnancy in first pregnancy Total No of women
Antihypertensive drug use in year after delivery
None
<3 months post 
partum
<3 months and 3-12 months post 
partum 3-12 months post partum only
Yes 23 826 21 216 1915 513 182
No 461 290 458 995 1335 276 684
*485 116 women had their first delivery in or after 1995; these women are included in the table, which also includes information on use of antihypertensive drugs from delivery until one year 
post partum. Of these women, 2144 did not enter follow-up (which began three months after delivery) because they were censored before this point due to, for example, development of heart 
disease. Consequently, in the text we state that the estimates of cumulative incidence are based on a slight smaller number of women (n=482 972).
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will develop hypertension after hypertensive disorders 
of pregnancy would be even more useful. Furthermore, 
the degree to which early identification and timely 
treatment of hypertension in women with a history of 
hypertensive disorders of pregnancy can reduce their 
burden of cardiovascular disease, is also unknown 
and needs to be clarified. In the quest to minimise the 
lifetime impact of hypertensive disorders of pregnancy 
on women’s post-pregnancy health, we now need data, 
particularly from randomised clinical trials, to support 
clinical decision making and policy on clinical follow-
up for women with a history of hypertensive disorders 
of pregnancy.
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